Aliskiren

A nonpeptide renin inhibitor (IC₅₀ = 0.6 nM) that selectively binds to the S3 sub-pocket of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby blocking eventual conversion to angiotensin II reduces blood

A nonpeptide renin inhibitor (IC₅₀ = 0.6 nM) that selectively binds to the S3 sub-pocket of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby blocking eventual conversion to angiotensin II reduces blood

Biochem/physiol Actions Aliskiren hemifumarate (ALS) has been used to treat hypertension, alone or with other antihypertensive medications. It is suitable for oral administration.

Biochem/physiol Actions Aliskiren hemifumarate (ALS) has been used to treat hypertension, alone or with other antihypertensive medications. It is suitable for oral administration.

Aliskiren is a direct renin inhibitor that exhibits antihypertensive, antithrombotic, and anti-angiogenic activities. Aliskiren binds to the S3bp binding site of renin, inhibiting its ability to cleave angiotensinin into angiotensin I, therefore

Aliskiren is a direct renin inhibitor that exhibits antihypertensive, antithrombotic, and anti-angiogenic activities. Aliskiren binds to the S3bp binding site of renin, inhibiting its ability to cleave angiotensinin into angiotensin I, therefore

Aliskiren is a direct renin inhibitor that exhibits antihypertensive, antithrombotic, and anti-angiogenic activities. Aliskiren binds to the S3bp binding site of renin, inhibiting its ability to cleave angiotensinin into angiotensin I, therefore